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Abstract
Background: Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose
in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public
concerns on vaccination coverage.
Methods: We used the Permanent Sample of Beneficiaries which was, at the time of the study, a representative
sample of 1/97th health insurance beneficiaries of the main Social Security scheme, the General Health Insurance
Scheme, covering approximately 77 % of the French resident population. We estimated HPV vaccination coverage
among girls born between 1995 and 1999 at their 15th, 16th and 17th birthday.
Results: The coverage for complete vaccination among 16 years old girls decreased from 26.5 % in the first
semester of 2011 to 18.6 % in the first semester of 2014.
Conclusions: HPV vaccination coverage was already low in 2011 and continued to decrease thereafter. Vaccines
reimbursement data allowed us to reactively monitor the impact of the controversy on vaccination coverage and
design counteracting measures.
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Background
In 2012, cervical cancer was the 11th most common
cancer in women in France with 3028 estimated new
cases and the 12th in terms of mortality with an esti-
mated 1 102 deaths [1]. The human papillomavirus
(HPV) is a necessary cause of cervical cancer [2]. In
addition to the opportunistic screening strategy based
on Pap smears recommended every 3 years for women
25 to 65 years old, HPV vaccination was introduced in
the immunisation schedule in 2007. Up to 2013, vaccin-
ation was recommended for girls aged 14 years old, with
a catch-up offered for girls aged 15–23 years old who
had not started their sexual life or in the year following
their sexual life debut [3]. Three doses were required for
a complete vaccination course [4].
In summer 2011, articles questioning HPV vaccine
safety were published in the lay media, telling the stories
of teenagers having developed neurological manifesta-
tions after HPV vaccination. A group of physicians
opposed to HPV vaccination organized several manifes-
tations including a public meeting with members of par-
liament, questioning the relevance of vaccination in
addition to pre-cancerous lesions screening. In October
2011, the High Council for Public Health issued a state-
ment reaffirming the favorable risk/benefit balance of
HPV vaccination [5]. In autumn 2013 the debate was
reopened with the decision of a Regional commission* Correspondence: d.levybruhl@invs.sante.fr
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for compensation for medical accidents which concluded
to the partial responsibility of the HPV vaccine in the
development of multiple sclerosis in a vaccinated adoles-
cent girl. This event was reported by the media.
Up to recently, the only routine source of vaccination
coverage among teenagers were the national school sur-
veys performed every six years at 15 years of age [6, 7].
Although providing reliable results, they were limited by
their poor timeliness. We therefore explored the rele-
vance of using vaccine reimbursement data to closely
monitor the impact of public concerns on HPV vaccin-
ation coverage.
Methods
HPV vaccination is almost exclusively administered in
France through the private sector. Patients purchase the
vaccine at pharmacies on a medical prescription. Virtu-
ally the whole French population is covered by the
National Health Insurance Scheme (NHIS) which covers
65 % of the price of the vaccine. A complementary in-
surance covers the remaining 35 % of the vaccine cost
for over 90 % of the population. This reimbursement
data are entered into a single database, the National
Health Insurance Information System, which contains
anonymous and comprehensive data on the health care
consumption of the entire French population.
In order to give access to a manageable database to
Public Health institutions, a sample of this huge
database, called the Permanent Sample of Beneficiaries
(PSB), was established in 2005. Through a decree signed
by the Minister of Health in 2005, the National Institute
for Public Health Surveillance (InVS) was given access
to the PSB, together with a restricted list of public insti-
tutions. At that time, the PSB was a representative sam-
ple of 1/97th health insurance beneficiaries covered by
the main scheme, the General Health Insurance Scheme,
covering approximately 77 % of the French resident
population. It included about 500,000 persons, followed
for all their health care consumptions for a period of at
least 20 years [8, 9].
We use the PSB to bi-annually monitor HPV vaccin-
ation coverage. The current analysis presents vaccination
data for girls born between 1995 and 1999 and aged
15 years between January 2010 and June 2014. We esti-
mated coverage at their 15th, 16th and 17th birthday. We
extracted data related to HPV vaccines purchased be-
tween July 2007 (date of first admission to reimburse-
ment by the NHIS of a HPV vaccine) and June 2014. We
extracted data from the date of the first admission to re-
imbursement as some girls may have been vaccinated
before 14 years of age, the marketing authorization of
both vaccines having been granted for girls from 9 years
of age. To take into account a possible delay between
vaccine purchase and availability of the information in
the PSB, we extracted the data in October 2014. For
each selected individual, we extracted his/her vaccine
history (number of doses reimbursed and age at
delivery). The age-specific vaccination coverage was cal-
culated by dividing, for each dose of vaccine, the number
of doses reimbursed by that age, by the number of eli-
gible girls of that age in the PSB. In order to assess more
precisely the potential impact of media on the HPV vac-
cination coverage we retrospectively estimate the vaccin-
ation coverage by quarter.
A decree dated 20th June 2005 gives to accredited
InVS staff access to anonymized individual PSB data.
This decree was issued after receiving a positive opinion
from the French Data Protection Agency (CNIL). The
author, who did the extraction and analysis, is accredited
for PSB database access.
Results
The vaccine coverage for at least one dose at the 15th
birthday varied very little from 23.7 % (95 % confidence
interval, CI [20.9–26.5]) to 26.5 % (95 % CI [24.1–28.9])
between 2010 and 2011. It decreased from 25.6 % (95 %
CI [23.3–27.9]) in the second semester of 2011 to 16.3 %
(95 % CI [14.3–18.3]) in the first semester of 2013 and
has remained below 18 % since (Table 1 and Fig. 1).
The vaccine coverage for the full series on the 16th
birthday varied very little from 26.5 % (95 % CI [23.6–
29.4]) in the first half of 2011 to 28.2 % (95 % CI [25.8–
30.6]) in the first half of 2012. It decreased from 28.2 %
(95 % CI [25.8–30.6]) in the first semester of 2012 to
18.6 % (95 % CI [16.5–20.7]) in the first semester of
2014. Coverage slightly increased between the 16th and
17th birthday through a limited catch up. However the
coverage among girls aged 17 years old decreased from
31.2 (95 % CI [28.6–33.6]) to 26.3 % (95 % CI [24.3–
28.6]) from the first semester of 2013 to the first semes-
ter of 2014 (Table 1). For girls born after 1996, the 3
doses vaccination coverage at any age decreased for suc-
cessive birth cohorts (Fig. 2).
Discussion
Even for the 1995 birth cohort who reached 16 years of
age at the time of the first publications in the lay media,
the coverage at 16 years was below 30 %. The one dose
HPV vaccine coverage dropped after the first publication
from 25.6 % at the end of 2011 to 19.8 % at the begin-
ning of 2012. We did not observe a second drop in vac-
cination coverage after the 2013 decision of a Regional
commission for compensation for medical accidents in
favor of the partial responsibility of the HPV vaccine in
the development of multiple sclerosis in an adolescent
girl. At this time the vaccination coverage was already
very low (17.5 % for 1 dose) which could explain that it
did not decreased further. Unfortunately, in 2011, the
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Table 1 HPV vaccination coverage (%) and its 95 % confidence interval at 15th, 16th and 17th birthday as of June 30 2014, France
Half year of
birthday
2010 2010 2011 2011 2012 2012 2013 2013 2014
s1 s2 s1 s2 s1 s2 s1 s2 s1
n 877 914 1316 1340 1431 1430 1323 1408 1404
1 dose at 15 23.7 [20.9–26.5] 24.7 [21.9–27.5] 26.5 [24.1–28.9] 25.6 [23.3–27.9] 19.8 [17.1–21.9] 17.5 [15.5–19.5] 16.3 [14.3–18.3] 17.5 [15.5–19.5] 17.7 [15.7–19.7]
3 doses at 16 – – 26.5 [23.6–29.4] 27.4 [24.5–30.3] 28.2 [25.8–30.6] 24.2 [21.9–26.5] 22.0 [19.9–24.1] 20.1 [18.0–22.2] 18.6 [16.5–20.7]













positive statement from the High Council for Public
Health was not reported in the media and therefore
could not impact favorably the HPV vaccination cover-
age. The social concerns related to the vaccine safety
profile and the relevance of HPV vaccination in addition
to screening are likely to have negatively affected HPV
vaccination coverage and contributed to the very low
level observed in 2014.
We were able to closely monitor the vaccination
coverage trends through the use of vaccine reimburse-
ment data. This new method represents an innovative

































Fig. 2 Cumulative vaccination coverage for 3 doses of HPV vaccine according to age and half year of birth. France
Fig. 1 Vaccination coverage with one dose of HPV vaccine at 15th birthday and three doses at 16th birthday, by quarter periods, January
2010–June 2014
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coverage estimates. The time between actual delivery of
the vaccine by the pharmacist and availability of the
information in the PSB is only around 1 month. Benefi-
ciaries are selected totally randomly. Indeed the benefi-
ciaries with a strictly secret value of their National
Identity Register (NIR) control key number (going from
1 to 97) are selected and included in the PSB whether
they have consumed care or not. The validity of the PSB
as a vaccine coverage measurement tool was previously
validated through the comparison of the mumps measles
and rubella (MMR) vaccination coverage estimated
through the PSB and through the Child Health Certificate
(CHC) which is our reference tool. MMR vaccine cover-
age estimates for one dose at 24 months for the 2010 birth
cohort was very close: 91.4 % from PSB and 90.5 %
through the CHC [10]. Our PSB estimates agree well with
the few available other data. Our 23.7 % coverage for
one dose among girls aged 15 years old in 2010 is
consistent with the results of a school survey in
which 24.7 % of girls aged on average 15 years old in
2009 had received one dose of HPV vaccine [5]. Our
estimated coverage for complete vaccination of 24.2 %
among girls aged 16 in 2012 is also consistent with
the results of a survey in which 23.6 % of girls aged
15 years old in 2012 were fully immunized against
HPV [11]. To our knowledge, except some experi-
ences in Germany [12, 13], reimbursement data has
not been used for the estimation of vaccination cover-
age in other European Countries [14]. It represents a
cheaper and easier alternative to ad hoc surveys
which can be very resource consuming. This source
of data is particularly useful to monitor coverage in
age groups such as teenagers usually not targeted by
vaccination strategies and for which routine vaccin-
ation monitoring tools are lacking in many countries.
The use of PSB has some limitations. First, our ana-
lysis focused on the beneficiaries of the General Health
Insurance Scheme covering only 77 % of the population
and no data comparing the vaccination attitudes of the
population according to their insurance coverage were
available until recently. However, since 2011, data from
two other schemes, covering an extra 10 % of the popu-
lation, have been progressively integrated in the PSB.
Vaccination coverage for one dose among 15 years old
girls born in 1998 covered by these schemes, was 18.9 %
(95 % CI [12.9–24.9]) and 18.5 % (95 % CI [12.6–24.3]),
respectively, consistent with our estimation (95 % CI
(17.8 % [16.4–19.2]). We were unable to estimate vaccin-
ation coverage after the age of 17 years because at this
age, many girls become students and are no longer regis-
tered in the General Health Insurance Scheme. Limited
information on factors that could have influenced the
vaccine coverage is available in the PSB. However, the
proportion of individuals registered in the PSB and
benefiting from the Universal Health Care Coverage,
which gives full free access to care to the most disadvan-
taged ones, did virtually not change during the study
period. This indicator can be considered as a proxy of
the socio-economic status of the PSB beneficiaries. Fur-
thermore, the vaccination offer did not change during
the study period.
Last, purchased vaccines may not all be administered
and some persons may purchase their vaccine without
claiming for reimbursement. There is no data to esti-
mate the frequency of such situations, but we believe
this to be very rare, especially for expensive vaccines
such as HPV ones.
Some measures have been taken to try to improve the
HPV vaccination coverage. A new report summarizing
internationally available evidence regarding the safety,
effectiveness and impact of HPV vaccination was pre-
pared by the Public Health Council (HCSP) and pub-
lished on its website on September 2014 to address the
controversy [15]. To the same end, the French Institute
for Health Promotion and Education has developed a
community management plan for HPV vaccination to be
implemented in 2016 in order to give official answers to
concerns raised and questions asked on internet forums.
Changes in the immunization schedule aiming at in-
creasing the compliance to HPV vaccination recommen-
dations has been made in 2014: the target age for
routine vaccination has been enlarged from 14 to 11–14
years and the number of doses needed in this age group
has been reduced from three to two [16].
Conclusions
In conclusion HPV vaccination coverage was very low in
France in 2011 and decrease afterwards probably in rela-
tion with media coverage regarding potential safety issues
of the vaccine. The Permanent Sample of Beneficiaries
was particularly useful to rapidly assess the impact of pub-
lic concerns on HPV vaccination coverage. A new vaccine
coverage assessment will be made by end-2015 and will
allow measuring the impact on the recently implemented
countermeasures on HPV vaccine coverage.
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